nach oben

Erschienen in:

19.07.2018 | original article

Austrian recommendations for the management of polycythemia vera

verfasst von: Sonja Burgstaller, Veronika Buxhofer-Ausch, Thamer Sliwa, Christine Beham-Schmid, Günther Gastl, Klaus Geissler, Thomas Melchardt, Maria Krauth, Peter Krippl, Andreas Petzer, Holger Rumpold, Albert Wölfler, Heinz Gisslinger

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 17-18/2018

Einloggen, um Zugang zu erhalten

Summary

Polycythemia vera (PV) is a clonal disease arising from hematopoietic stem cells. Erythrocytosis is the hallmark of the disease but leukocytosis, thrombocytosis and splenomegaly may also be present. Thromboembolic complications occur in about 20% of patients. Circulatory disturbances as well as pruritus represent frequent symptoms of the disease. Mutations in the JAK2 gene are present in 95% of patients in exon 14 (V617F) and in 3% in exon 12. The main goal of the treatment for patients with PV is the prevention of thromboembolic events, transformation to myelofibrosis and acute myeloid leukemia. Interferon alpha and hydroxyurea are used as first-line treatment for high risk patients. For patients unresponsive to first-line therapy ruxolitinib is available.

Vorheriger Artikel Diagnosis of Helicobacter pylori infection

Nächster Artikel Schatzki ring

Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27:1874–81.CrossRefPubMedPubMedCentral

Ania BJ, Suman VJ, Sobell JL, Codd MB, Silverstein MN, Melton LJ 3rd. Trends in the incidence of polycythemia vera among Olmsted County, Minnesota residents, 1935–1989. Am J Hematol. 1994;47:89–93.CrossRefPubMed

Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–90.CrossRefPubMed

Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocytemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7:387–97.CrossRefPubMed

James C, Ugo V, Le Couédic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythemia vera. Nature. 2005;434:1144–8.CrossRefPubMed

Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365:1054–61.CrossRefPubMed

Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 eon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med. 2007;356:459–68.CrossRefPubMedPubMedCentral

Mullally A, Lane SW, Ball B, Megerdichian C, Okabe R, Al-Shahrour F, et al. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells. Cancer Cell. 2010;17:584–96.CrossRefPubMedPubMedCentral

Hasan S, Lacout C, Marty C, Cuingnet M, Solary E, Vainchenker W, et al. JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFN alpha. Blood. 2013;122:1464–77.CrossRefPubMed

10.

Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, et al. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice. Blood. 2008;111:3931–40.CrossRefPubMed

11.

Grisouard J, Li S, Kubovcakaova L, Rao TN, Meyer SC, Lundberg P, et al. JAK2 exon 12 mutant mice display isolated erythrocytosis and changes in iron metabolism favoring increased erythropoiesis. Blood. 2016;128:839–51.CrossRefPubMed

12.

Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114:937–51.CrossRefPubMed

13.

Tefferi A, Lasho TL, Gugioelmelli P, Finke CM, Totunno G, Elala Y, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21–30.CrossRefPubMedPubMedCentral

14.

Siegel FP, Tauscher J, Petrides PE. Aquagenic pruritus in polycythemia vera: characteristics and influence on quality of life in 441 patients. Am J Hematol. 2013;88:665–9.CrossRefPubMed

15.

Michiels JJ. Erythromelalgia and vascular complications in polycythemia vera. Semin Thromb Hemost. 1997;23:441–54.CrossRefPubMed

16.

Torgano G, Mandelli C, Massaro P, Abbiati C, Ponzetto A, Bertinieri G, et al. Gastroduodenal lesions in polycythemia vera: frequency and role of Helicobacter pylori. Br J Haematol. 2002;117:198–202.CrossRefPubMed

17.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.CrossRefPubMed

18.

Barbui T, Thiele J, Gisslinger H, Finazzi G, Carobbio A, Rumi E, et al. Masked polycythemia vera (mPV): results of an international study. Am J Hematol. 2014;89:52–4.CrossRefPubMed

19.

Lussana F, Carobbio A, Randi ML, Rumi EC, Finazzi G, et al. A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythemia vera. Br J Haematol. 2014;167:541–6.CrossRefPubMed

20.

Barbui T, Thiele J, Passamonti F, Rumi E, Boveri E, Randi ML, et al. Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome. Blood. 2012;119:2239–41.CrossRefPubMed

21.

Berlin NI. Diagnosis and classification of the polycythemias. Semin Hematol. 1975;12:339–51.PubMed

22.

Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, et al. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29:761–70.CrossRefPubMedPubMedCentral

23.

Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, et al. A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia. 2010;24:1574–9.CrossRefPubMed

24.

Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment of polycythemia vera. N Engl J Med. 2013;368:22–33.CrossRefPubMed

25.

Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil treatment. N Engl J Med. 1981;304:441–7.CrossRefPubMed

26.

Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–24.CrossRefPubMed

27.

Michiels JJ, Berneman Z, Schroyens W, Koudstaal PJ, Lindemans J, Nemann HA, et al. Platelet-mediated erythromelalgia, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: Platelets. 2006;17:528–44. a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.CrossRefPubMed

28.

Passamonti F, Rumi E, Randi ML, Morra E, Cazzola M. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010;8:411–3.CrossRefPubMed

29.

Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706–15.CrossRefPubMed

30.

Kiladjian JJ, Cassinat B, Chevret S, Turlurle P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112:3065–72.CrossRefPubMed

31.

Quintas-Cardama A, Kantarjian H, Manshuouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–24.CrossRefPubMedPubMedCentral

32.

Gisslinger H, Zagrijtschuk O, Buxhofer-Ausch V, Thaler J, Schloegl E, Gastl GA, et al. Ropeginterferon alfa-2b, a novel IFN alfa-2b, induces high response rates with low toxicity in patients with polycythemia vera. Blood. 2015;126:1762–9.CrossRefPubMedPubMedCentral

33.

Gisslinger H, Klade C, Georgiev P, Krochmalczyk D, Gercheva L, Egyed M, et al. Ropeginterferon alfa-2b induces high rates of clinical, hematological and molecular responses in polycythemia vera: two-year results from the first prospective randomized controlled trial. Blood. 2017;130:320.

34.

Najean Y, Rain J‑D. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood. 1997;90:3370–7.PubMed

35.

Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain J‑D. Treatment of polycythemia vera with Hydroxyurea and Pipibroman: final results of a randomized trial initiated in 1980. J Clin Oncol. 2011;29:3907–13.CrossRefPubMed

36.

Alvarez-Larran A, Kerguelen A, Hernandez-Boluda JC, Perez-Encinas M, Ferrer-Marin F, Barez A, et al. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythemia vera. Br J Haematol. 2016;172:786–93.CrossRefPubMed

37.

Antonioli E, Gugliemelli P, Pieri L, Finazzi M, Rumi E, Martinelli V, et al. Hydroxyurea-related toxicity in 3411 patients with Ph-negative MPN. Am J Hematol. 2012;87:552–4.CrossRefPubMed

38.

Latagliata R, Spadea A, Cedrone M, Ki Giandonenico J, De Muro M, Villivà N, et al. Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the mister Hyde face of a sage drug. Cancer. 2012;118:404–9.CrossRefPubMed

39.

Verstovsek S, Passamonti F, Rambaldi A, Barosi G, Rosen PJ, Rumi E, et al. A phase 2 study of Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea. Cancer. 2014;120:513–20.CrossRefPubMed

40.

Vanucchi AM, Kiladjian JJ, Griesshammer M, Masszi T, Durrant S, Passamonti F, et al. Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015;372:426–35.CrossRef

41.

Passamonti F, Griesshammer M, Palandri F, Egyed M, Benevolo G, Devos T, et al. Ruxolitinib for the treatment of inadequately controlled polycythemia vera without splenomegaly (RESPONSE-2): a randomized, open-label, phase 3b study. Lancet Oncol. 2017;18:88–99.CrossRefPubMed

42.

Vanucchi AM, Verstovsek S, Gugliemelli P, Griesshammer M, Burn TC, Naim A, et al. Ruxolitnib reduces JAK2p.V617F allele burden in patients with polycythemia vera enrolled in the RESPONSE study. Ann Hematol. 2017;96:1113–20.CrossRef

43.

Heine A, Brossart P, Wolf D. Ruxolitnibis a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843–4.CrossRefPubMed

44.

Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–90.CrossRefPubMed

45.

Smalberg JH, Arends LR, Valla DC, Kiladjian JJ, Janssen HL, Leebeek FW. Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis. Blood. 2012;120:4921–8.CrossRefPubMed

46.

Mancuso A. An update on the management of Budd-Chiari-syndrome: the issues of timing and choice of treatment. Eur J Gastroenterol Hepatol. 2015;27:200–3.CrossRefPubMed

47.

De Stefano V, Qi X, Betti S, Rossi E. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment. Thromb Haemost. 2016;115:240–9.CrossRefPubMed

48.

Griesshammer M, Struve S, Barbui T. Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy. Blood Rev. 2008;22:235–45.CrossRefPubMed

Titel: Austrian recommendations for the management of polycythemia vera
verfasst von: Sonja Burgstaller
Veronika Buxhofer-Ausch
Thamer Sliwa
Christine Beham-Schmid
Günther Gastl
Klaus Geissler
Thomas Melchardt
Maria Krauth
Peter Krippl
Andreas Petzer
Holger Rumpold
Albert Wölfler
Heinz Gisslinger
Publikationsdatum: 19.07.2018
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe 17-18/2018
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-018-1359-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 17-18/2018

Schatzki ring

Extravascular lung water index and Halperin score to predict outcome in critically ill patients

Predictors of colonic pathologies in active acromegaly: single tertiary center experience

Veranstaltungstipps

Ruxolitinib therapy for myelofibrosis in Austria

Diagnosis of Helicobacter pylori infection